MINNEAPOLIS, May 09, 2022 (GLOBE NEWSWIRE) — Nuwellis, Inc. (NUWE) today announced the presentation of three Aquadex-related abstracts at the annual meeting of the Pediatric Academic Societies (PAS). This research was supported in part by unrestricted grants from Nuwellis to the University of Alabama at Birmingham (UAB). Other sources of funding include the Nuwellis-funded Ultrafiltration Therapy Registry using Aquadex – Pediatric (ULTRA-Peds) and the National Kidney Collaborative (NKC). PAS, the first national meeting for pediatric research, was held in Denver, Colorado, April 21-25, 2022.

“We are excited to add to the ever-growing body of research supporting the negative impact of excess fluid and the benefits of Aquadex,” said Nestor Jaramillo, Jr., President and CEO of Nuwellis. “I am grateful to the leader of these projects, Dr. David Askenazi, for his extensive research into the benefits of ultrafiltration for pediatric patients. »

Aquadex SmartFlow® ultrafiltration provides gentle, precise and adjustable fluid removal, helping to achieve the desired fluid balance with only 35ml (approximately 2.5 tablespoons) of blood outside the body. The customizable fluid removal rate is especially important for pediatric patients, who have a small amount of blood in their body. Aquadex is cleared by the FDA for use in adults and pediatric patients weighing 20 kg (44 lbs) or more.

“Ultrafiltration using the Aquadex system provides an easy-to-use, safe and effective therapy for managing fluid balance in pediatric patients,” said Dr. Askenazi. “I am grateful for the company’s commitment and proud to partner with Nuwellis to provide meaningful data that helps the medical community determine when and how to implement Aquadex for people with pediatric kidney disease. . »

About Nuwellis
Nuwellis, Inc. (NUWE) is a medical device company dedicated to transforming the lives of patients with fluid overload through science, collaboration and innovation. The Company is focused on developing, manufacturing and marketing the Aquadex SmartFlow® system for ultrafiltration therapy. Nuwellis is headquartered in Minneapolis, Minnesota with a wholly owned subsidiary in Ireland.

About the Aquadex SmartFlow System
The Aquadex SmartFlow System offers clinically proven therapy using a simple, flexible and smart method to remove excess fluid in patients with hypervolemia (fluid overload). The Aquadex SmartFlow System is indicated for temporary (up to 8 hours) or prolonged (greater than 8 hours in patients requiring hospitalization) use in adult and pediatric patients weighing 20 kg or more whose fluid overload does not respond to medical management, including diuretics. All treatments should be administered by a healthcare provider, in an outpatient or inpatient clinical setting, under medical prescription, both of whom have received training in extracorporeal therapies.

Forward-looking statements
Certain statements in this release may be deemed to be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, without limitation, statements regarding new market opportunities and expected growth in 2022 and beyond. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, therefore, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements contained in this release, including, without limitation, risks associated with our ability to execute our go-to-market strategy, the impact of the pandemic of COVID-19, the possibility that we may be unable to raise sufficient funds necessary for our planned operations, our post-marketing clinical data collection activities, the benefits of our products to patients, our expectations for the development of products and marketing efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, protection of intellectual property, our ability to integrate acquired businesses, our expectations regarding anticipated synergies and benefits of acquired businesses, and other risks and t uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date they are made. Nuwellis undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.